skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8121

Aripiprazole for late-life schizophrenia

Review

(2133) Views  (581) Full article downloads

Authors: Jeffrey Rado, Philip G Janicak

Published Date August 2010 Volume 2010:5 Pages 253 - 258
DOI: http://dx.doi.org/10.2147/CIA.S9398

Jeffrey Rado, Philip G Janicak

Psychiatric Clinical Research Center, Rush University Medical Center, Chicago, IL, USA

Abstract: Antipsychotics are frequently used in elderly patients to treat a variety of conditions, including schizophrenia. While extensively studied for their impact in younger ­populations, there is comparatively limited evidence about the effectiveness of these agents in older patients. Further complicating this situation are the high co-morbidity rates (both psychiatric and ­medical) in the elderly; age-related changes in pharmacokinetics leading to a heightened proclivity for adverse effects; and the potential for multiple, clinically relevant drug interactions. With this background in mind, we review diagnostic and treatment-related issues specific to elderly patients suffering from schizophrenia and other psychotic conditions, focusing on the potential role of aripiprazole.

Keywords: aripiprazole, schizophrenia, elderly, dopamine partial antagonist